NCT00124579 · REGISTRY CONDITION SEARCH

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: TERMINATED
Registry last update: 2018-08-09

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. It may also stop the growth of cancer by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with thalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with thalidomide and dexamethasone works in treating patients with relapsed or refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Toxicity Evaluation

→

outcome · POSTED

Overall Response Rate Complete Remission (CR), Remission (R), and Partial Remission (PR).

→

outcome · POSTED

Progression-Free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma (MM) * Active disease * Relapsed or refractory disease after ≥ 1 prior therapy for MM, that may have included autologous or allogeneic stem cell transplantation * Relapse is defined as the occurrence of any of the following during or after prior treatment: * Myeloma protein level increase by \> 100% from the lowest previously recorded level * Myeloma protein level increase above the defined response criteria for partial remission * Reappearance of any myeloma peak that had disappeared during the prior treatment * Increase in the size and number of lytic bone lesions and/or focal lesions by x-ray, MRI, positron emission tomography, and/or CT scan * Refractory disease is defined as no response (i.e., not achieving complete remission, remission, or partial remission) to prior therapy * Measurable disease * No evidence of POEMS (polyneuropathy, organomegaly, endocrinopathy, presence of M-protein, and skin changes) syndrome * Must be registered on protocol SWOG-S0334 PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Zubrod 0-2 (unless due to bone pain) Life expectancy * Not specified Hematopoietic * Absolute neutrophil count \> 1,000/mm\^3 * Platelet count \> 50,000/mm\^3 Hepatic * AST or ALT ≤ 3 times upper limit of normal (ULN) * Bilirubin ≤ 3 times ULN Renal * Creatinine clearance \> 30 mL/min Cardiovascular * No New York Heart Association class III or IV congestive heart failure * No myocardial infarction within the past 6 months * No poorly controlled hypertension Other * Not pregnant or nursing * Negative pregnancy test * Fertile female patients must use effective double method contraception for ≥ 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment (during and for 4 weeks after completion of study treatment for male patients) * No blood, ova, or sperm donation during study treatment * No active infection requiring antibiotics * No neurotoxicity ≥ grade 2 * No diabetes mellitus * No other serious medical or psychiatric illness that would preclude study treatment * No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics Chemotherapy * At least 14 days since prior chemotherapy (28 days for nitrosoureas) and recovered Endocrine therapy * Not specified Radiotherapy * At least 14 days since prior radiotherapy and recovered Surgery * Not specified Other * No prior bortezomib alone or combined with thalidomide * Concurrent participation on protocol SWOG-S0309 allowed
healthy Volunteers: false
maximum Age: 120 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
bortezomib with thalidomide and dexamethasone
intervention Names
Drug: bortezomib
Drug: dexamethasone
Drug: thalidomide
label
bortezomib with thalidomide and dexamethasone
type
EXPERIMENTAL

interventions

arm Group Labels
bortezomib with thalidomide and dexamethasone
description
induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
name
bortezomib
type
DRUG
arm Group Labels
bortezomib with thalidomide and dexamethasone
description
induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
name
dexamethasone
type
DRUG
arm Group Labels
bortezomib with thalidomide and dexamethasone
description
100 mg/d PO days 1-21 every 21 days
name
thalidomide
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 7
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Responses are defined as follows: Complete Remission: Absence of bone marrow or blood findings of multiple myeloma. This includes disappearance of all evidence of serum and urine M-proteins on immunofixation electrophoresis studies. Normalization of serum concentrations of normal immunoglobulins is not required for CR. There must also be no evidence of increasing anemia. Bone marrow cellularity must be ≥ 20% with plasma cells ≤ 5%. Remission: A ≥ 75% reduction in the serum M-protein, and if a urine M-protein (Bence-Jones protein) is present, either a ≥ 90% reduction in this protein, or a urine M-protein \< 0.2gm/day. Bone marrow plasma cells must be ≤ 5%. Partial Remission: A ≥ 50% reduction in the serum M-protein, and if present, a ≥ 50% reduction in the urine M-protein (Bence-Jones protein). Bone marrow plasma cells must not be increased from baseline level.
measure
Overall Response Rate Complete Remission (CR), Remission (R), and Partial Remission (PR).
time Frame
1 year

secondary Outcomes

description
To evaluate the qualitative and quantitative toxicities associated with this regimen.
measure
Toxicity Evaluation
time Frame
From date of protocol therapy start to date of protocol therapy end, i.e., up to about 3.5 years
description
From date of initial registration to date of progression/relapse of disease (\> 25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc.) or death from any cause, whichever came first, up to 5 years
measure
Progression-Free Survival
time Frame
about 12-18 months

Full study description

brief Summary: RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. It may also stop the growth of cancer by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with thalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with thalidomide and dexamethasone works in treating patients with relapsed or refractory multiple myeloma.
detailed Description: OBJECTIVES: * Determine the confirmed overall response rate (complete remission, remission, and partial remission) in patients with relapsed or refractory multiple myeloma treated with bortezomib, thalidomide, and dexamethasone. * Determine overall and progression-free survival of patients treated with this regimen. * Determine the qualitative and quantitative toxic effects of this regimen in these patients. * Correlate, preliminarily, treatment with bortezomib with the activation of osteoblasts in these patients. OUTLINE: This is a multicenter study. * Induction therapy: Patients receive bortezomib IV on days 1, 4, 8, and 11, oral thalidomide once daily on days 1-21, and oral dexamethasone once daily on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days until achievement of confirmed complete remission (CR), remission (R), or partial remission (PR) OR for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving confirmed CR, R, or PR who reach a plateau prior to receiving the maximum 8 courses of induction therapy OR who achieve confirmed CR, R, or PR after receiving the maximum 8 courses of induction therapy proceed to maintenance therapy. Patients achieving stable disease after receiving the maximum 8 courses of induction therapy either proceed to maintenance therapy or receive further treatment with bortezomib, thalidomide, and dexamethasone off-study. * Maintenance therapy: Patients receive oral dexamethasone on days 1-4. Courses repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed within 30 days and then every 6 months for up to 5 years. PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 18 months.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f29ea5bd095f5fb83202
requested nct id
NCT00124579
primary nct id
NCT00124579
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
85f9ad8eae92cefd3fd722c01f99fa9db86c114ef40a02a63a39e6faf2a54492
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f29ea5bd095f5fb83202
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00124579
occurrences
context exact
NCT00124579
end
11
exact text
NCT00124579
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/662/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
10608fda01a71ccd95358dae42e27e3d4a3a61ae97cb2a8116762c1d5e79b66d
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice